Piracetam
CLINICAL USE
Myoclonus
DOSE IN NORMAL RENAL FUNCTION
7.2 g daily in 2–3 divided doses titrated to a maximum of 20 g daily
PHARMACOKINETICS
Molecular weight                           :142.2 %Protein binding                           :15 %Excreted unchanged in urine     : >90 Volume of distribution (L/kg)       :0.7half-life – normal/ESRD (hrs)      :5/Increased DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
50–80 4.8 g in 2–3 divided doses30–50 1.2 g twice daily20–30 1.2 g daily<20 Contraindicated DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Likely dialysability. Avoid. Contraindicated HD                     :Dialysed. Avoid. Contraindicated HDF/high flux   :Dialysed. Avoid. Contraindicated CAV/VVHD      :Unknown dialysability. Dose as in GFR=20–30 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
–
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home